Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation.
about
The Human Papillomavirus 16 E7 Oncoprotein Attenuates AKT Signaling To Promote Internal Ribosome Entry Site-Dependent Translation and Expression of c-MYC.Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.MicroRNA-10b inhibits proliferation, migration and invasion in cervical cancer cells via direct targeting of insulin-like growth factor-1 receptor.NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibitionPathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.Comparison of human papillomavirus detection between freshly frozen tissue and paraffin embedded tissue of invasive cervical cancer.TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentIntegrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancerTargeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitroProgression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.Combining targeted therapies: practical issues to consider at the bench and bedside.PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.Overexpression of OLC1, cigarette smoke, and human lung tumorigenesis.The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer.Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.Emerging biological treatments for uterine cervical carcinoma.Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing.A Review of mTOR Pathway Inhibitors in Gynecologic CancerOncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Deoxyelephantopin impairs growth of cervical carcinoma SiHa cells and induces apoptosis by targeting multiple molecular signaling pathways.Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer.PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways.A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I.Mitogen-activated protein kinases activate the nuclear localization sequence of human papillomavirus type 11 E1 DNA helicase to promote efficient nuclear import.The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.Systematic module approach identifies altered genes and pathways in four types of ovarian cancer.
P2860
Q30277065-A79691BF-9A6D-4A3D-A623-FD421E835F71Q30494717-0EF7280D-8552-470F-80FC-D0B8B430FEDAQ33684710-968D713D-8A34-4CDC-B540-597777BD137CQ33750980-F0E2838D-93EF-4F28-8ADD-44A3DCEE72E9Q33878632-306CDD59-2493-4F16-A634-6FD774EF621CQ33880093-7FEDBAA2-80A6-4053-80C9-8423A9058378Q34123402-BDF4C1B4-D806-44BE-A64F-44AF680C568DQ34193299-6ABFBD2D-9399-415B-8D87-14D6F489DA4AQ34198635-A403D540-7D6D-43F5-B583-C0635CC37CF5Q34239911-5D4C3D71-A2F1-4D07-9E22-FC233D02DAFDQ34508976-86853C7D-431B-4EF2-9AC0-27570295C2A8Q34794711-BC8E4A3F-8B37-4843-84E6-3A6A2947128DQ34957243-50CF0776-2A6D-47C3-8BCA-707DD5348DABQ35089274-A6C4624D-79D6-49FA-8BB5-9F8707D5F008Q35552023-0F9FF2DA-8011-4036-9F69-5D1573D18DEFQ35583672-9654393C-D9CB-4E70-B405-E5E7004B6840Q35651134-B4FFCF88-634D-4DE9-A624-834C703B7B73Q35781357-70D57965-E5F1-4C2E-88A9-C845A167A299Q35821113-CBB50ECF-77DB-4A74-942C-04E2567CFDD2Q35838573-BD4B1A25-6BD3-4481-8EB9-D06B610A82A5Q35848973-D4A0648D-C3D0-4985-A61D-13A034B3580DQ35885555-A29642E7-A86A-4B22-8543-C329020E27FCQ36610847-6CD53D09-62F0-46F0-930F-28DD0BC704C7Q36746834-197761F8-A920-41F3-A12A-579E73FB4AC0Q36771946-11D3860F-72AC-4A91-A2F6-47DEED8F41E8Q37009828-0A783B3E-BE53-4021-8CC3-C698128EB8AFQ37036792-A9E592E7-62D3-44DB-B9EE-F0946D7921BCQ37540968-B7AABC00-9080-40E5-971A-3D75AE011F12Q37578026-24F6218F-AD7B-45B5-BBAE-D4172C80EAB3Q37668889-9806A32D-C0E4-4721-B715-C644BB969D88Q37678092-CC5C3302-59D7-46C8-A424-ACE12C7B6A69Q37767709-4E8FF07E-62B3-49C1-8B19-4D299D238C92Q38953040-2600FD20-3860-4D75-87E4-C3D1A22F14BCQ38974852-8D3D8125-9E8B-4E37-A09D-CC5D2B8B4F94Q39050475-70AC68D6-BE0B-4191-86B7-09B740FCD4DBQ39426030-2310524B-FC6E-4590-AB63-8337B1D6DA57Q39748979-7FA234A3-1662-49B7-959F-DDF27AD86C68Q40162029-629C2F9E-6069-4C62-82D8-C4811E5F1F0DQ40366431-E1F18C02-FE0D-4295-8FFE-9718D3E36DFDQ41990579-363F4BBA-1250-4095-A7CD-C74141371358
P2860
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@en
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@nl
type
label
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@en
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@nl
prefLabel
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@en
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@nl
P2093
P2860
P356
P1476
Molecular analysis of the PI3K ...... ation and AKT phosphorylation.
@en
P2093
Bjørn I Bertelsen
Roar Sandvei
Solrun J Steine
P2860
P304
P356
10.1002/IJC.21461
P577
2006-04-01T00:00:00Z